ATLASATLAS fair value
ATLAS has no fair value for this stock today.
VolitionRx (VNRX)
VolitionRx stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · NYSE
$0.19▲ +2.78%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
45%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on VolitionRx in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On VolitionRx
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives VolitionRx a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.16 and $0.21; in 9 out of 10, between $0.12 and $0.28. Estimated annual volatility is 86%.
Key numbers
- Revenue (12 months)
- $2.5M
- Revenue growth (YoY)
- +40.0%
- Gross margin
- 0.0%
- Return on equity
- 65.6%
- Free cash flow (12 months)
- $-9.2M
- Beta
- 1.10
What this means
ATLAS does not publish a fair value for VNRX right now, but it does show its odds of rising: close to a coin flip.
Its beta is 1.10: it moves roughly in line with the market.
About the company
VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis.
Want to see everything about VolitionRx?
Get started →Plans from €3.99 a month.
Frequently asked questions
What does VolitionRx do?
VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis.
What is the chance VNRX goes up next month?
45%: close to a coin flip. In half of the simulated outcomes, VNRX ends the month between $0.16 and $0.21.
How volatile is VNRX?
ATLAS estimates annual volatility at 86%. In a typical month, half of the outcomes end between $0.16 and $0.21.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer